A carregar...
Phase II Study of Weekly Paclitaxel as Third-Line Chemotherapy for Advanced or Recurrent Gastric Cancer (OGSG0602)
BACKGROUND: Median survival time was longer than 1 year in recent randomized phase III studies in advanced or recurrent gastric cancer (GC) conducted in Japan. Although progression-free survival after first-line chemotherapy has improved, many patients go on to receive second-line or later therapies...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Society of Gastrointestinal Oncology
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3056307/ |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|